About Aposture Surgical
Aposture Surgical is a Technology company based in Seoul (South Korea) founded in 2024. It develops minimally invasive tools and AI systems for spinal disorder treatments. It operates on a B2B model. Aposture Surgical has raised $87 thousand across 1 funding round. Aposture Surgical offers products and services including PLEF, ApostureFlex, and ApostureVision AI. Its focus areas include Healthcare, Medical Devices, Spinal Surgery and AI-Guided Procedures. Its legal entity is Aposture Surgical Corporation.
Company details
Aposture Surgical focuses on creating novel treatments for spinal conditions, including ultra-minimally invasive procedures like PLEF for lumbar stenosis and ApostureFlex for spinal fusion. They integrate AI through ApostureVision to guide surgeries visually, aiming for long-term patient stability. Based in the United States, their innovations target healthcare providers to address global back pain issues.
- Headquarters Seoul, South Korea
- SectorsTechnology
- Website aposturesurgical.com
- Legal Name Aposture Surgical Corporation
- Total Equity Funding$87K (USD)
in 1 rounds
- Latest Funding Round$87K (USD), Seed
Aug 2026
Products & Services of Aposture Surgical
Aposture Surgical offers a comprehensive portfolio of products and services, including PLEF, ApostureFlex, and ApostureVision AI.
Ultra-minimally invasive treatment for lumbar spinal stenosis.
System for spinal fusion to prevent post-operative degeneration.
AI platform for visual guidance in spinal surgeries.
Funding Insights of Aposture Surgical
Aposture Surgical has successfully raised a total of $87K through 1 strategic funding round. The most recent funding activity was a Seed round of $87 thousand completed in August 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $87,000
- Total Rounds 1
- Last Round Seed — $87,000
- First Round $87,000
(Aug 2026)
All 1 funding rounds of Aposture Surgical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2026 | $87,000 | Seed | – | – | – |
Timeline of Aposture Surgical
2 dated milestones of Aposture Surgical across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Aposture Surgical is founded.
- Funding First funding round of $87K.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Aposture Surgical
Aposture Surgical was founded in 2024 and raised its 1st funding round 2 years after it was founded.
Aposture Surgical is headquartered in Seoul, South Korea.
Aposture Surgical is a funded company, having raised a total of $87K across 1 funding round to date. The company's 1st funding round was a Seed of $87K, raised on Aug 2026.
Aposture Surgical focuses on creating novel treatments for spinal conditions, including ultra-minimally invasive procedures like PLEF for lumbar stenosis and ApostureFlex for spinal fusion. They integrate AI through ApostureVision to guide surgeries visually, aiming for long-term patient stability. Based in the United States, their innovations target healthcare providers to address global back pain issues.
Aposture Surgical offers PLEF, ApostureFlex, and ApostureVision AI.
Aposture Surgical operates through Aposture Surgical Corporation.